0LKB.L - Vanda Pharmaceuticals Inc.
| Previous close | 6.34 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 190 |
| Market cap | 3.217M |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | 0.19 |
| EPS (TTM) | 0.32 |
| Earnings date | 01 Aug 2023 - 07 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Motley FoolWhy Vanda Pharmaceuticals Stock Crawled Higher Today
Earnings season seems to be the pill needed to improve sentiment on Vanda Pharmaceuticals (NASDAQ: VNDA). The commercial-stage biotech saw its share price rise by almost 1% on Thursday, following the release of quarterly results that comfortably topped analyst estimates. The sleep medication's sales were higher in the same period one year ago when it brought in $44 million.
ZacksVanda Pharmaceuticals (VNDA) Lags Q3 Earnings and Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of -40% and 8%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksAre Investors Undervaluing Exelixis (EXEL) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ZacksShould Value Investors Buy Dynavax Technologies (DVAX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ZacksVanda Pharmaceuticals (VNDA) Q2 Earnings and Revenues Miss Estimates
Vanda (VNDA) delivered earnings and revenue surprises of -54.55% and 3.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksBluebird (BLUE) Surges 18%: Is This an Indication of Further Gains?
Bluebird (BLUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.